Statistically significant area under the curve analysis from Mesoblast’s Phase II stem cell product in refractory rheumatoid arthritis (RA) shows that the week 12 positive responses are maintained for 39 weeks. This suggests that the indication could progress into pivotal studies and may attract potential partners. We have increased the RA probability to 35% (formerly 20%). Mesoblast has entered a nine-month exclusive negotiation with Mallinckrodt (for an A$29.6m investment) on chronic
28 Feb 2017
Continued positive RA responses
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Continued positive RA responses
Mesoblast Limited (MSB:ASX) | 0 0 -2.3% | Mkt Cap: 591.5m
- Published:
28 Feb 2017 -
Author:
Dr John Savin - Pages:
Statistically significant area under the curve analysis from Mesoblast’s Phase II stem cell product in refractory rheumatoid arthritis (RA) shows that the week 12 positive responses are maintained for 39 weeks. This suggests that the indication could progress into pivotal studies and may attract potential partners. We have increased the RA probability to 35% (formerly 20%). Mesoblast has entered a nine-month exclusive negotiation with Mallinckrodt (for an A$29.6m investment) on chronic